VANCOUVER, British Columbia and WARMINSTER, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ABUS, an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:
- Jefferies 2017 Global Healthcare Conference, June 6-9, 2017, New York, and
- JMP Securities Life Sciences Conference, June 20-21, 2017, New York.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: acutler@arbutusbio.com Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: ttolmie@arbutusbio.com Media David Schull Russo Partners Phone: 858.717.2310 Email: david.schull@russopartnersllc.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
